In this context, studies have focused more on the role of TGFβ in shaping the tumor-promoting TME in CRC, supporting the potential of TGFβ inhibition in cancer immunotherapy [4,6,8,9,10]. This evidence concerns the gene TGFB1 and neoplasm.